SOBI.ST Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 13:09):

Stats
Dzisiejszy wolumen	111 214
Średni wolumen	552 496
Kapitalizacja rynkowa	95.10B
EPS	SEK0 ( 2024-04-24 )
Następna data zysków	( SEK0.560 ) 2024-07-15
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	44.34
ATR14	SEK0.322 (0.12%)

Wolumen Korelacja

Długi: 0.07 (neutral)

Krótki: 0.76 (moderate)

Signal:(41.762) Neutral

Swedish Orphan Biovitrum Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Swedish Orphan Biovitrum Korelacja - Waluta/Towar

0.10
( neutral )

-0.30
( neutral )

0.82
( strong )

0.43
( neutral )

0.50
( neutral )

-0.68
( moderate negative )

Swedish Orphan Biovitrum Finanse

Annual	2023
Przychody:	SEK22.12B
Zysk brutto:	SEK14.05B (63.52 %)
EPS:	SEK7.47

FY	2023
Przychody:	SEK22.12B
Zysk brutto:	SEK14.05B (63.52 %)
EPS:	SEK7.47

FY	2022
Przychody:	SEK18.79B
Zysk brutto:	SEK14.01B (74.58 %)
EPS:	SEK8.52

FY	2021
Przychody:	SEK15.53B
Zysk brutto:	SEK12.05B (77.56 %)
EPS:	SEK9.09

Financial Reports:

No articles found.

Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.